Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 505 DKK 2.99%
Market Cap: 2.2T DKK

EV/EBIT
Enterprise Value to EBIT

16.5
Current
25.6
Median
16.3
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
16.5
=
Enterprise Value
2.2T DKK
/
EBIT
135.3B DKK
Market Cap EV/EBIT
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 16.5
US
Eli Lilly and Co
NYSE:LLY
733.3B USD 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.4B USD 16.4
CH
Roche Holding AG
SIX:ROG
213.3B CHF 11.3
CH
Novartis AG
SIX:NOVN
190.2B CHF 14.2
UK
AstraZeneca PLC
LSE:AZN
167B GBP 197.7
US
Merck & Co Inc
NYSE:MRK
199.6B USD 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
US
Pfizer Inc
NYSE:PFE
136.3B USD 10.5
FR
Sanofi SA
PAR:SAN
109.7B EUR 5.6
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
CSE:NOVO B
Average EV/EBIT: 1 698.1
16.5
14%
1.2
US
Eli Lilly and Co
NYSE:LLY
38.8
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.3
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.7
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1
FR
Sanofi SA
PAR:SAN
5.6
14%
0.4

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
14.5
2-Years Forward
EV/EBIT
12.3
3-Years Forward
EV/EBIT
10.9